CoChat

In vitro Development of Controlled-Release Nanoniosomes for Improved Delivery and Anticancer Activity of Letrozole for Breast Cancer Treatment

Open access

The DOI matches its Crossref record; 85 of the 86 references it cites were found in a registry or an index, and 1 are not checked yet.

Abstract

Introduction: Breast cancer is among the most prevalent mortal cancers in women worldwide. In the present study, an optimum formulation of letrozole, letrozole-loaded niosome, and empty niosome was developed, and the anticancer effect was assessed in in vitro MCF-7, MCF10A and MDA-MB-231 breast cancer cell lines. Materials and Methods: Various niosomal formulations of letrozole were fabricated through thin-film hydration method and characterized in terms of size, polydispersity index (PDI), morphology, entrapment efficiency (EE%), release kinetics, and stability. Optimized niosomal formulation of letrozole was achieved by response surface methodology (RSM). Antiproliferative activity and the mechanism were assessed by MTT assay, quantitative real-time PCR, and flow cytometry. Furthermore, cellular uptake of optimum formulation was evaluated by confocal electron microscopy. Results: The formulated letrozole had a spherical shape and showed a slow-release profile of the drug after 72 h. The size, PDI, and eEE% of nanoparticles showed higher stability at 4°C compared with 25°C. The drug release from niosomes was in accordance with Korsmeyer–Peppa’s kinetic model. Confocal microscopy revealed the localization of drug-loaded niosomes in the cancer cells. MTT assay revealed that all samples exhibited dose-dependent cytotoxicity against breast cancer cells. The IC 50 of mixed formulation of letrozole with letrozole-loaded niosome (L + L 3 ) is the lowest value among all prepared formulations. L+L 3 influenced the gene expression in the tested breast cancer cell lines by down-regulating the expression of Bcl 2 gene while up-regulating the expression of p53 and Bax genes. The flow cytometry results revealed that L + L 3 enhanced the apoptosis rate in both MCF-7 and MDA-MB-231 cell lines compared with the letrozole (L), letrozole-loaded niosome (L 3 ), and control sample. Conclusion: Results indicated that niosomes could be a promising drug carrier for the delivery of letrozole to breast cancer cells. Graphical Abstract: Keywords: breast cancer, niosome, letrozole, drug delivery system, anticancer

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2147/ijn.s384085

Cites

85 of 86 references verified0 citation errors · 0 not checkable

Statistics

Figures

Graphical abstract
Graphical abstract CC BY-NC · PubMed Central
Figure 1 (A–F) Graphical presentation of the average size distribution of L1, L1B, L2, L2B, L3 and L3B respectively. Morphological characterization of optimized niosomes: (G) scanning electron microscopy (SEM), (H) transmission electron microscopy (TEM), and (I) Atomic force microscopy (AFM).
Figure 1 (A–F) Graphical presentation of the average size distribution of L1, L1B, L2, L2B, L3 and L3B respectively. Morphological characterization of optimized niosomes: (G) scanning electron microscopy (SEM), (H) transmission electron microscopy (TEM), and (I) Atomic force microscopy (AFM).CC BY-NC · PubMed Central
Figure 2 (A) Fourier Transform Infrared FTIR Spectra of (a) Cholesterol, (b) Span80, (c) DCP, (d) L, (e) L3B, and (f) L3). (B) XRD patterns of (a) L, (b) L3B, and (c) L3. DSC thermograms of (C) L3B, (D) L and (E) L3. (F) In vitro drug release profile of free letrozole and release profile of letrozole in optimum formulation of letrozole-loaded niosomes (L1, L2 and L3). Data are represented as mean ± SD.
Figure 2 (A) Fourier Transform Infrared FTIR Spectra of (a) Cholesterol, (b) Span80, (c) DCP, (d) L, (e) L3B, and (f) L3). (B) XRD patterns of (a) L, (b) L3B, and (c) L3. DSC thermograms of (C) L3B, (D) L and (E) L3. (F) In vitro drug release profile of free letrozole and release profile of letrozole in optimum formulation of letrozole-loaded niosomes (L1, L2 and L3). Data are represented as mean ± SD.CC BY-NC · PubMed Central
Figure 3 (A–C) Size stability evaluation of L1 (A), L2 (B) and L3 (C) formulations, (D–F) PDI stability evaluation of L1 (D), L2 (E) and L3 (F) formulations, (G–I) EE (%) stability evaluation of L1 (G), L2 (H) and L3 (I) formulations. Data are represented as mean ± SD and n=3; ***P<0.001, **P<0.01, *P<0.05.
Figure 3 (A–C) Size stability evaluation of L1 (A), L2 (B) and L3 (C) formulations, (D–F) PDI stability evaluation of L1 (D), L2 (E) and L3 (F) formulations, (G–I) EE (%) stability evaluation of L1 (G), L2 (H) and L3 (I) formulations. Data are represented as mean ± SD and n=3; ***P<0.001, **P<0.01, *P<0.05.CC BY-NC · PubMed Central
Figure 4 (A) The effect of L3B, (B) L, (C) L3 and (D) L+L3 samples on the viability of MCF10A cells. Data are represented as mean ± SD and n=3; ***P<0.001, **P<0.01, *P<0.05.
Figure 4 (A) The effect of L3B, (B) L, (C) L3 and (D) L+L3 samples on the viability of MCF10A cells. Data are represented as mean ± SD and n=3; ***P<0.001, **P<0.01, *P<0.05.CC BY-NC · PubMed Central
Figure 5 (A–H) The drug concentration effect of L3B, L, L3 and L+L3 samples on the viability of (A–H) MCF-7 and (E–H) MDA-MB-231 cells. Data are represented as mean ± SD and n=3; ***P<0.001, **P<0.01, *P<0.05.
Figure 5 (A–H) The drug concentration effect of L3B, L, L3 and L+L3 samples on the viability of (A–H) MCF-7 and (E–H) MDA-MB-231 cells. Data are represented as mean ± SD and n=3; ***P<0.001, **P<0.01, *P<0.05.CC BY-NC · PubMed Central
Figure 6 Schematic of cytotoxicity assay of letrozole from a niosome (A); IC50 values for MCF-7 cells after 48 h and 72 h treatment (B); Comparison between IC50 values in the different formulations in the different time points for MCF-7 cells (C); IC50 values for MDA-MB-231 cells after 48 h and 72 h treatment (D); Comparison between IC50 values in the different formulations in the different time points for MDA-MB-23 cells (E). Data are represented as mean ± SD and n=3; P<0.001***.
Figure 6 Schematic of cytotoxicity assay of letrozole from a niosome (A); IC50 values for MCF-7 cells after 48 h and 72 h treatment (B); Comparison between IC50 values in the different formulations in the different time points for MCF-7 cells (C); IC50 values for MDA-MB-231 cells after 48 h and 72 h treatment (D); Comparison between IC50 values in the different formulations in the different time points for MDA-MB-23 cells (E). Data are represented as mean ± SD and n=3; P<0.001***.CC BY-NC · PubMed Central
Figure 7 (A) The expression of apoptosis BAXax, Bcl2BCL2 and Pp53 genes in treated cancerous cells; (B–D) The expression of Bax, Bcl2 and p53 genes in MCF-7, and (E–G) in MDA-MB-231 cells after treatment with different samples. The IC50 was used for each sample. Data are represented as mean ± SD and n=3; ***P<0.001, **P<0.01, *P<0.05.
Figure 7 (A) The expression of apoptosis BAXax, Bcl2BCL2 and Pp53 genes in treated cancerous cells; (B–D) The expression of Bax, Bcl2 and p53 genes in MCF-7, and (E–G) in MDA-MB-231 cells after treatment with different samples. The IC50 was used for each sample. Data are represented as mean ± SD and n=3; ***P<0.001, **P<0.01, *P<0.05.CC BY-NC · PubMed Central
Figure 8 (A) The apoptosis assay of the breast cancer cells treated by different formulations of letrozole; (B) The flow cytometry of MCF-7 and (C) MDA-MB-231 cells after treatment with different samples. Different quadrants in the scatter plot of double variable flow cytometry could reveal the following information: the Q1 quadrant (FITC−/PI+): necrotic cells; the Q2 quadrant (FITC+/PI+): late apoptotic cells; Q3 quadrant (FITC+/PI−): early apoptotic cells; and the Q4 quadrant (FITC−/PI−): living cells. Data are represented as mean ± SD. (D) The quantitative apoptosis rate analysis of MCF-7 cells and (E) MDA-MB-231 cells after treatment with different samples. Data are represented as mean ± SD and n=3; ***P<0.001, **P<0.01.
Figure 8 (A) The apoptosis assay of the breast cancer cells treated by different formulations of letrozole; (B) The flow cytometry of MCF-7 and (C) MDA-MB-231 cells after treatment with different samples. Different quadrants in the scatter plot of double variable flow cytometry could reveal the following information: the Q1 quadrant (FITC−/PI+): necrotic cells; the Q2 quadrant (FITC+/PI+): late apoptotic cells; Q3 quadrant (FITC+/PI−): early apoptotic cells; and the Q4 quadrant (FITC−/PI−): living cells. Data are represented as mean ± SD. (D) The quantitative apoptosis rate analysis of MCF-7 cells and (E) MDA-MB-231 cells after treatment with different samples. Data are represented as mean ± SD and n=3; ***P<0.001, **P<0.01.CC BY-NC · PubMed Central
Figure 9 (A) Cell cycle analysis of MCF-7 and (B) MDA-MB-231 cells treated by different formulations of niosomes by the same concentration of the drug. (C) Cell cycle distribution for MCF-7 cells and (D) MDA-MB-231 cells after treatment with different samples. The control sample refers to the cells without treatment with any drug or nanomaterial. Data are represented as mean ± SD.
Figure 9 (A) Cell cycle analysis of MCF-7 and (B) MDA-MB-231 cells treated by different formulations of niosomes by the same concentration of the drug. (C) Cell cycle distribution for MCF-7 cells and (D) MDA-MB-231 cells after treatment with different samples. The control sample refers to the cells without treatment with any drug or nanomaterial. Data are represented as mean ± SD.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 86 references

Research works printed but not linked: 17

  1. Bray, 2018, CA, 68, 394
  2. Sarhadi, 2020, Trans Appl Sci, 6, 309
  3. Cohen, 2002, Clin Cancer Res, 8, 665
  4. 2020, Niosomal Delivery of Simvastatin to MDA-MB-231 Cancer Cells
  5. Azizi, 2015, J Chem Pharm Res, 7, 423
  6. Nowroozi, 2018, Iran J Pharm Sci, 17, 1
  7. 2020, Optimization and Characterization of Tannic Acid Loaded Niosomes for Enhanced Antibacterial and Anti-Biofilm Activities
  8. Dash, 2010, Acta Pol Pharm, 67, 217
  9. 2015, Strategies to Modify the Drug Release from Pharmaceutical Systems
  10. Sadeghi, 2020, Pharm Chem J, 53, 1, 10.1007/s11094-020-02100-6 · DOI
  11. Lawrence, 1996, STP Pharma Sci, 6, 49
  12. Seras-Cansell, 1996, STP Pharma Sci, 6, 12
  13. Pardakhty, 2011, DARU J Pharm Sci, 19, 404
  14. Trunet, 1993, J Clin Endocrinol Metab, 77, 319, 10.1210/jcem.77.2.8345034 · doi:10.1210/jcem.77.2.8345034 · Paper page
  15. Radwan, 2021, J Pharm Innov, 17, 1
  16. Khorani, 2022, J. Alzheimer’s Dis, 1
  17. Amiri, 2016, Asian Pac J Cancer Prev, 17, 3835

Cited by

See all 44

Metadata

Authors
Ahmadi, S., Seraj, M., Chiani, M., Hosseini, S., Bazzazan, S., Akbarzadeh, I., Saffar, S., & Mostafavi, E.
Affiliations
  • Pasteur Institute of Iran (IR)
  • Shahid Beheshti University (IR)
  • Stanford Medicine (US)
Corresponding author
Mostafavi, Ebrahim
Venue
International Journal of Nanomedicine
Published
2022-12
Volume
Volume 17
Pages
6233-6255
ISSN
  • 1176-9114 (ISSN-L)
  • 1178-2013
OpenAlex
W4311260165
Cited by
44
References
85
Citations by year
2026: 10 · 2025: 12 · 2024: 10 · 2023: 10 · 2022: 2
FWCI
2.12
Type
journal article
Language
en
Open access
Locations
  • International Journal of Nanomedicine (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
Funders
  • Pasteur Institute of Iran
  • National Institute of Biomedical Imaging and Bioengineering (T32EB009035)
Topics
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advancements in Transdermal Drug Delivery
Keywords
letrozole, niosomes, breast cancer, controlled drug release, anticancer drug delivery, apoptosis, Bcl-2, p53, Bax, MCF-7 cells, MDA-MB-231 cells, MCF10A cells, cytotoxicity, Korsmeyer-Peppas kinetics, encapsulation efficiency, cellular uptake
MeSH terms
Letrozole, Breast Neoplasms, Delayed-Action Preparations, Female, Humans, Liposomes, MCF-7 Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: In vitro Development of Controlled-Release Nanoniosomes for Improved Delivery and Anticancer Activity of Letrozole for Breast Cancer Treatment. https://app.cochat.ai/papers/10.2147/ijn.s384085
The paper
Ahmadi, S., Seraj, M., Chiani, M., Hosseini, S., Bazzazan, S., Akbarzadeh, I., Saffar, S., & Mostafavi, E. (2022). In vitro Development of Controlled-Release Nanoniosomes for Improved Delivery and Anticancer Activity of Letrozole for Breast Cancer Treatment. International Journal of Nanomedicine. https://doi.org/10.2147/ijn.s384085

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.